H. Lundbeck A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLBBF research report →
About the company
H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily specializes in therapeutic solutions for psychiatric and neurological disorders across Europe, North America, and other worldwide regions.
- CEO
- Charl van Zyl
- IPO
- 2022
- Employees
- 5,707
- HQ
- Valby, DK
Price Chart
- Market Cap
- $5.23B
- P/E
- 11.58
- P/S
- 1.36
- P/B
- 1.67
- EV/EBITDA
- 5.54
- Div Yield
- 2.67%
- Gross Margin
- 78.95%
- Op Margin
- 27.86%
- Net Margin
- 14.71%
- ROE
- 14.81%
- ROIC
- 11.62%
- Revenue
- $24.30B · 10.42%
- Net Income
- $3.18B · 1.33%
- EPS
- $3.21 · 1.26%
- Op Income
- $6.33B
- FCF YoY
- 56.98%
- 52W High
- $7.55
- 52W Low
- $5.15
- 50D MA
- $6.94
- 200D MA
- $6.71
- Beta
- 0.26
- Avg Volume
- 64
Get TickerSpark's AI analysis on HLBBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HLBBF coverage
Recent articles, reports, and earnings notes.
No research on HLBBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLBBF report →Similar companies
Peers in the same neighborhood.